⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 10, 2024European Journal of CancerOpen Access

PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors

Tanja Abu Sabbah Sarah Theurer Hideo A. Baba Smiths Lueong Jassin Rashidi‐Alavijeh Thomas Hilser Yasmin Zaun Martin Metzenmacher Michael Pogorzelski Isabel Virchow Ina Pretzell Karina Kostbade Jürgen Treckmann Marcel Wiesweg Martin Schüler Stefan Kasper Gregor Zaun

View Full Paper

Ask AI

Bookmark

Share

Abstract

Cancer of unknown primary (CUP) is a heterogeneous entity with limited overall survival (OS) in most patients. Prognostic biomarkers are needed, particularly for treatment stratification. We investigated the impact of programmed death-ligand 1 (PD-L1) expression as prognostic marker in immunotherapy-naïve CUP patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sabbah et al. (2024) studied this question.

synapsesocial.com/papers/68e5cc66b6db6435875628c8 https://doi.org/10.1016/j.ejca.2024.114268

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site2024 · 3 citations
2Programmed death-ligand 1 expression in carcinoma of unknown primary2024 · 3 citations
3PD-L1 Expression as a Predictor of Time to Progression in Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Single-Center StudyCohort Study · 2026
4PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancerPrognostic Study · 2022 · 15 citations
5Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trialRCT · 2022 · 48 citations